Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial

Gail J. Roboz; Hartmut Döhner; Christopher Pocock; Hervé Dombret; Farhad Ravandi; Jun Ho Jang; Dominik Selleslag; Jiří Mayer; Uwe M. Martens; Jane Liesveld; Teresa Bernal; Ming Chung Wang; Peiwen Yu; Ling Shi; Shien Guo; Ignazia La Torre; Barry Skikne; Qian Dong; Julia Braverman; Salem Abi Nehme; C. L. Beach; Andrew H. Wei

doi:10.3324/haematol.2021.279174

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial

Gail J. Roboz
, Hartmut Döhner
, Christopher Pocock
, Hervé Dombret
, Farhad Ravandi
, Jun Ho Jang
, Dominik Selleslag
, Jiří Mayer
, Uwe M. Martens
, Jane Liesveld
, Teresa Bernal
, Ming Chung Wang
, Peiwen Yu
, Ling Shi
, Shien Guo
, Ignazia La Torre
, Barry Skikne
, Qian Dong
, Julia Braverman
, Salem Abi Nehme

C. L. Beach, Andrew H. Wei

Cornell University
New York Presbyterian Hospital
Ulm University
East Kent Hospitals University NHS Foundation Trust
Université Paris Cité
University of Texas Health Science Center at Houston
Sungkyunkwan University
AZ Sint-Jan Brugge-Oostende AV
Masaryk University
SLK-Kliniken
University of Rochester
Hospital Universitario Central de Asturias
Chang Gung Medical Foundation
Pharmaceutical Product Development
Bristol-Myers Squibb
University of Kansas
Monash University

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	3240-3244
Number of pages	5
Journal	Haematologica
Volume	106
Issue number	12
DOIs	https://doi.org/10.3324/haematol.2021.279174
State	Published - Dec 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3324/haematol.2021.279174

Cite this

Roboz, G. J., Döhner, H., Pocock, C., Dombret, H., Ravandi, F., Jang, J. H., Selleslag, D., Mayer, J., Martens, U. M., Liesveld, J., Bernal, T., Wang, M. C., Yu, P., Shi, L., Guo, S., Torre, I. L., Skikne, B., Dong, Q., Braverman, J., ... Wei, A. H. (2021). Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial. Haematologica, 106(12), 3240-3244. https://doi.org/10.3324/haematol.2021.279174

@article{79757b74c76a4a57a891d781d0bba138,

title = "Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial",

author = "Roboz, \{Gail J.\} and Hartmut D{\"o}hner and Christopher Pocock and Herv{\'e} Dombret and Farhad Ravandi and Jang, \{Jun Ho\} and Dominik Selleslag and Ji{\v r}{\'i} Mayer and Martens, \{Uwe M.\} and Jane Liesveld and Teresa Bernal and Wang, \{Ming Chung\} and Peiwen Yu and Ling Shi and Shien Guo and Torre, \{Ignazia La\} and Barry Skikne and Qian Dong and Julia Braverman and Nehme, \{Salem Abi\} and Beach, \{C. L.\} and Wei, \{Andrew H.\}",

year = "2021",

month = dec,

doi = "10.3324/haematol.2021.279174",

language = "English",

volume = "106",

pages = "3240--3244",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

Roboz, GJ, Döhner, H, Pocock, C, Dombret, H, Ravandi, F, Jang, JH, Selleslag, D, Mayer, J, Martens, UM, Liesveld, J, Bernal, T, Wang, MC, Yu, P, Shi, L, Guo, S, Torre, IL, Skikne, B, Dong, Q, Braverman, J, Nehme, SA, Beach, CL & Wei, AH 2021, 'Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial', Haematologica, vol. 106, no. 12, pp. 3240-3244. https://doi.org/10.3324/haematol.2021.279174

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial. / Roboz, Gail J.; Döhner, Hartmut; Pocock, Christopher et al.
In: Haematologica, Vol. 106, No. 12, 12.2021, p. 3240-3244.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission

T2 - Results from the phase III, placebo-controlled QUAZAR AML-001 trial

AU - Roboz, Gail J.

AU - Döhner, Hartmut

AU - Pocock, Christopher

AU - Dombret, Hervé

AU - Ravandi, Farhad

AU - Jang, Jun Ho

AU - Selleslag, Dominik

AU - Mayer, Jiří

AU - Martens, Uwe M.

AU - Liesveld, Jane

AU - Bernal, Teresa

AU - Wang, Ming Chung

AU - Yu, Peiwen

AU - Shi, Ling

AU - Guo, Shien

AU - Torre, Ignazia La

AU - Skikne, Barry

AU - Dong, Qian

AU - Braverman, Julia

AU - Nehme, Salem Abi

AU - Beach, C. L.

AU - Wei, Andrew H.

PY - 2021/12

Y1 - 2021/12

UR - https://www.scopus.com/pages/publications/85120738327

U2 - 10.3324/haematol.2021.279174

DO - 10.3324/haematol.2021.279174

M3 - Letter

C2 - 34551506

AN - SCOPUS:85120738327

SN - 0390-6078

VL - 106

SP - 3240

EP - 3244

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial

UN SDGs

Access to Document

Other files and links

Cite this